Nanoparticles: A Vaccine Adjuvant for Subcutaneous Administration

Tasana Pitaksuteepong

Authors

Tasana Pitaksuteepong Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok 65000,Thailand.

Abstract

Subcutaneous administration is the most appropriate route for delivering an antigen because the antigen can drain directly from the injection site to lymph nodes where immunocompetent cells reside. Nanoparticles, having a size ranging from 1-1,000 nm, are considered as the most promising adjuvant for subcutaneous immunization. This article is aimed to review the studies relating to the investigation of nanoparticles efficiency to elicit the immune response following subcutaneous administration and to determine if the nanoparticles are actually capable to enhance immune response. Factors influencing the achievement and the magnitude of immune induction are also included.

References

Alonso, A. J., Gupta, P. K., Min, C., Siber, G. R., & Langer, R. (1994). Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine,12, 299-306.

Bodmeier, R., & Chen, H. (1990). Indomethacin polymeric nanosuspensions prepared by microfluidization. Journal of Controlled Release,12, 223-233.

Bodmeier, R., & McGinity, J. W. (1987). The preparation and evaluation of drug containing poly (D,L-lactide) microspheres fomed by solvent evaporation. Pharmaceutical Research,4, 465-471.

Cancer Research UK. (2001). The lymphatic system. Retrieved February 8, 2002, from http://www.cancerhelp.org.uk/help/default.asp?page=117.

Conway, M. A., Madrigal-Estebas, L., McClean, S., Brayden, D. J., & Mills, K. H. G. (2001). Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: Effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine,19, 1940-1950.

Coombes, A. G. A., Lavelle, E. C., Jenkins, P. G., & Davis, S. S. (1996). Single dose, polymeric, microparticle-based vaccines: The influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine,14, 1429-1438.

Diwan, M., Tafaghodi, M., & Samuel, J. (2002). Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. Journal of Controlled Release, 85, 247-262.

Hawley, A. E., Davis, S. S., & Illum, L. (1995). Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Advanced Drug Delivery Reviews, 17, 129-148.

Higuchi, M., Fokin, A., Masters, T. N., Robicsek, F., & Schmid-Schonbein, G. W. (1999).

Transport of colloidal particles in lymphatics and vasculature after subcutaneous injection. Journal of Applied Physiology, 86, 1381-1387.

Ikomi, F., Hanna, G. K., & Schmid-Schonbein, G. W. (1999). Size- and surface-dependent uptake of colloid particles into the lymphatic system. Lymphology,32, 90-102.

Ikomi, F., Hanna, G. K., & Schmid-Schonbein, G. W. (1995). Mechanism of colloidal particle uptake into the lymphatic system: Basic study with percutaneous lymphography. Radiology, 196, 107-113.

Jeffery, H., Davis, S. S., & O' Hagan, D. T. (1993). The preparation and characterization of poly(lactide-co-glycolide) microparticles: II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharmaceutical Research, 10, 362-368.

Jelley-Gibbs, D. M., Lepak, N. M., Yen, M., & Swain, S. L. (2000). Two distinct stages in the transition from naive CD4 T cells to effectors, early antigen-dependent and late cytokine-driven expansion and differentiation. Journal of Immunology,165, 5017-5026.

Kreuter, J. (1992). Physicochemical characterization of nanoparticles and their potential for vaccine preparation. Vaccine Research, 1, 93-98.

Kreuter, J. (1994). Nanoparticles. In J. Kreuter (Ed.), Colloidal drug delivery systems (pp. 219-342). New York: Marcel Dekker.

Kreuter, J., & Haenzel, I. (1978). Mode of action of immunological adjuvants: Some physicochemical factors influencing the effectivity of polyacrylic adjuvants. Infection and Immunity, 19, 667-675.

Kreuter, J., & Liehl, E. (1981). Long-term studies of microencapsulated and adsorbed influenza vaccine nanoparticles. Journal of Pharmaceutical Sciences, 70, 367-371.

Kreuter, J., Liehl, E., Berg, U., Soliva, M., & Speiser, P. P. (1988). Influence of hydrophobicity on the adjuvant effect of particulate polymeric adjuvants. Vaccine,6, 253-256.

Kreuter, J., Mauler, R., Gruschkau, H., & Speiser, P. P. (1976). The use of new polymethylmethacrylate adjuvants for split influenza vaccines. Experimental Cell Biology, 44, 12-19.

Kreuter, J., & Speiser, P. P. (1976). New adjuvants on a polymethylmethacrylate base. Infection and Immunity, 13, 204-210.

Krieg, A. M. (2001). Immune effects and mechanisms of action of CpG motifs. Vaccine, 19, 618-622.

Lemoine, D., & Preat, V. (1998). Polymeric nanoparticles as delivery system for influenza virus glycoproteins. Journal of Controlled Release, 54, 15-27.

Newman, M. J., & Powell, M. F. (1995). Immunological and formulation design considerations for subunit vaccines. In M. F. Powell & M. J. Newman (Eds.), Vaccine Design: The Subunit and Adjuvant Approach (pp. 1-42). New York: Plenum Press.

O'Hagan, D. T. (1997). Recent advances in vaccine adjuvants for systemic and mucosal administration. Journal of Pharmacy and Pharmacology, 49, 1-10.

Oussoren, C., & Storm, G. (2001). Liposomes to target the lymphatics by subcutaneous administration. Advanced Drug Delivery Reviews, 50, 143-156.

Pitaksuteepong, T. (2002). Evaluation of nanocapsules for antigen delivery. Unpublished doctoral dissertation, University of Otago, Dunedin.

Pitaksuteepong, T., Davies, N. M., Baird, M. A., & Rades, T. (2004). Uptake of antigen encapsulated in polyethylcyanoacrylate nanocapsules by D1-dendritic cells. DIE PHARMZIE, 59, 134-142.

Porter, C. J. H. (1997). Drug delivery to the lymphatic system. Critical Reviews in Therapeutic Drug Carrier Systems, 14, 333-393.

Potter, T. (2002). Overview of the immune system. Retrieved May 10, 2002, from http://mcdb.colorado.edu/courses/4300/Lecture1.pdf.

Raghuvanshi, R. J., Mistra, A., Talwar, G. P., Levy, R. J., & Labhasetwar, V. (2001). Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid. Journal of Microencapsulation, 18, 723-732.

Schmid-Schonbein, G. W., & Zweifach, B. W. (1994). Fluid pump mechanisms in initial lymphatics. News In The Physiological Sciences, 9, 67-71.

Singh, J., Somavarapu, S., Bramwell, C., McHugh, C., Shah, K., & Alpar, O. (2001, June). Comparative study of nanospheres composed of various blends of poly

(D,L-lactic acid), poly(lactic-co-glycolic acid) and poly-e-caprolactone polymers as vaccine adjuvants for diphtheria toxoid. Paper presented at 28th International Symposium on Controlled Release of Bioactive Materials, San Diego, CA.

Stieneker, F., Kersten, G., Blois, V., Crommelin, D. J. A., Hem, S. L., Lower, J., et al. (1995). Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine,13, 45-53.

Stieneker, F., & Kreuter, J. (1994). Nanoparticles as a potential antigen delivery system. In J. L. Cleland & R. Langer (Eds.), Formulation and delivery of proteins and peptides (pp. 306-321). Washington, DC: American Chemical Society.

Watnasirichaikul, S., Davies, N. M., Rades, T., & Tucker, I. G. (2000). Preparation of biodegrad able insulin nanocapsules from biocompatible microemulsions. Pharmaceutical Research, 17, 684-689.